Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

20 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Multiple-dose ponezumab for mild-to-moderate Alzheimer's disease: Safety and efficacy.
Landen JW, Cohen S, Billing CB Jr, Cronenberger C, Styren S, Burstein AH, Sattler C, Lee JH, Jack CR Jr, Kantarci K, Schwartz PF, Duggan WT, Zhao Q, Sprenger K, Bednar MM, Binneman B. Landen JW, et al. Among authors: cronenberger c. Alzheimers Dement (N Y). 2017 May 10;3(3):339-347. doi: 10.1016/j.trci.2017.04.003. eCollection 2017 Sep. Alzheimers Dement (N Y). 2017. PMID: 29067341 Free PMC article.
Ponezumab in mild-to-moderate Alzheimer's disease: Randomized phase II PET-PIB study.
Landen JW, Andreasen N, Cronenberger CL, Schwartz PF, Börjesson-Hanson A, Östlund H, Sattler CA, Binneman B, Bednar MM. Landen JW, et al. Alzheimers Dement (N Y). 2017 Jun 8;3(3):393-401. doi: 10.1016/j.trci.2017.05.003. eCollection 2017 Sep. Alzheimers Dement (N Y). 2017. PMID: 29067345 Free PMC article.
Safety and pharmacokinetics of PF-04360365 following a single-dose intravenous infusion in Japanese subjects with mild-to-moderate Alzheimer's disease: a multicenter, randomized, double-blind, placebo-controlled, dose-escalation study.
Miyoshi I, Fujimoto Y, Yamada M, Abe S, Zhao Q, Cronenberger C, Togo K, Ishibashi T, Bednar MM, Kupiec JW, Binneman B. Miyoshi I, et al. Among authors: cronenberger c. Int J Clin Pharmacol Ther. 2013 Dec;51(12):911-23. doi: 10.5414/CP201816. Int J Clin Pharmacol Ther. 2013. PMID: 24131736 Clinical Trial.
Long-term Efficacy, Safety, and Immunogenicity of the Infliximab (IFX) Biosimilar, PF-06438179/GP1111, in Patients with Rheumatoid Arthritis After Switching from Reference IFX or Continuing Biosimilar Therapy: Week 54-78 Data From a Randomized, Double-Blind, Phase III Trial.
Cohen SB, Radominski SC, Kameda H, Kivitz AJ, Tee M, Cronenberger C, Zhang M, Hackley S, Rehman MI, von Richter O, Alten R. Cohen SB, et al. Among authors: cronenberger c. BioDrugs. 2020 Apr;34(2):197-207. doi: 10.1007/s40259-019-00403-z. BioDrugs. 2020. PMID: 31939063 Free PMC article. Clinical Trial.
Long-term efficacy, safety, and immunogenicity of the adalimumab biosimilar, PF-06410293, in patients with rheumatoid arthritis after switching from reference adalimumab (Humira®) or continuing biosimilar therapy: week 52-92 data from a randomized, double-blind, phase 3 trial.
Fleischmann RM, Alvarez DF, Bock AE, Cronenberger C, Vranic I, Zhang W, Alten R. Fleischmann RM, et al. Among authors: cronenberger c. Arthritis Res Ther. 2021 Sep 25;23(1):248. doi: 10.1186/s13075-021-02626-4. Arthritis Res Ther. 2021. PMID: 34563243 Free PMC article. Clinical Trial.
Randomized, Open-Label, Single-Dose, Parallel-Group Pharmacokinetic Study of PF-06410293 (adalimumab-afzb), an Adalimumab Biosimilar, by Subcutaneous Dosing Using a Prefilled Syringe or a Prefilled Pen in Healthy Subjects.
Cox DS, Alvarez DF, Bock AE, Cronenberger CL. Cox DS, et al. Among authors: cronenberger cl. Clin Pharmacol Drug Dev. 2021 Oct;10(10):1166-1173. doi: 10.1002/cpdd.939. Epub 2021 Mar 25. Clin Pharmacol Drug Dev. 2021. PMID: 33765358 Free PMC article. Clinical Trial.
A comparative clinical study of PF-06410293, a candidate adalimumab biosimilar, and adalimumab reference product (Humira®) in the treatment of active rheumatoid arthritis.
Fleischmann RM, Alten R, Pileckyte M, Lobello K, Hua SY, Cronenberger C, Alvarez D, Bock AE, Sewell KL. Fleischmann RM, et al. Among authors: cronenberger c. Arthritis Res Ther. 2018 Aug 15;20(1):178. doi: 10.1186/s13075-018-1676-y. Arthritis Res Ther. 2018. PMID: 30111357 Free PMC article. Clinical Trial.
20 results